Pancreatic cancer-associated diabetes mellitus is characterized by reduced β-cell secretory capacity, rather than insulin resistance
Diabetes Research and Clinical Practice — Bao J, Liu D, Sun J, et al. | February 10, 2022
Compared to type 2 diabetes mellitus (T2DM) patients, those with pancreatic cancer associated diabetes (PaCDM) were found to have a lower baseline and postprandial insulin and C-peptide secretion. PaCDM patients exhibited decreased insulin secretion and improved peripheral sensitivity than T2DM patients.
In this study of 44 participants who underwent mixed meal tolerance test (MMTT), experts examined the differences between the pancreatic and gut endocrine hormones of patients with PaCDM and T2DM.
PaCDM patients exhibited blunted insulin and C-peptide responses to MMTT than T2DM patients.
Differences existed in baseline concentrations and AUCs.
Lower insulin secretion capacity but better insulin sensitivity was detected in PaCDM patients vs T2DM patients.
In the T2DM group, higher peak concentration and AUC of pancreatic polypeptide were evident compared to healthy controls, but in accordance with PaCDM.
PaCDM patients had lower baseline glucagon-like peptide-1 levels relative to T2DM patients.
No between-group differences were observed for glucagon and gastric inhibitory peptide.